Immunic, Inc. (IMUX) vs Outlook Therapeutics, Inc. (OTLK)
A side-by-side comparison of Immunic, Inc. and Outlook Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMUX
Immunic, Inc.
$7.87HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
OTLK
Outlook Therapeutics, Inc.
$0.58HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — IMUX vs OTLK
growth of $100 · dividends reinvested · last 10yIMUX -99.7% (-43.5%/yr)OTLK -99.9% (-50.4%/yr)IMUX compounded faster over this window
IMUX OTLK
IMUX vs OTLK: by the numbers
- •OTLK is the larger company ($108M vs $107M market cap).
- •Both run net losses; IMUX's is the smaller (0.00% vs -4416.22% net margin).
Metrics side by side
Valuation
| Metric | IMUX | OTLK |
|---|---|---|
| P/B ratio | 0.84 | N/A |
Profitability
| Metric | IMUX | OTLK |
|---|---|---|
| Gross margin | 0.00% | 46.49% |
| Operating margin | 0.00% | -4744.25% |
| Net margin | 0.00% | -4416.22% |
| ROE | -87.45% | N/A |
| ROIC | -92.16% | -352.19% |
Growth (annualized)
| Metric | IMUX | OTLK |
|---|---|---|
| Total return CAGR (5Y) | -35.70% | -57.40% |
Frequently asked
- How have IMUX and OTLK total returns compared?
- Over the past 10 years, IMUX delivered -43.80% and OTLK delivered -50.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.